Literature DB >> 29672887

Young age is associated with increased rates of residual and recurrent paediatric differentiated thyroid carcinoma.

Sarah Hampson1, Derek Stephens2, Jonathan D Wasserman3,4.   

Abstract

OBJECTIVE: Differentiated thyroid carcinoma is rare in young children. There are conflicting data as to whether disease in this age group differs from that in adolescents and specifically, if it is more aggressive. Current practice guidelines do not differentiate treatment between these groups, but speculate that differences may exist. We sought to compare clinical features, treatment and outcomes between children (<12 years) and adolescents (12-18 years) with thyroid nodules and thyroid malignancy over a 20-year period.
DESIGN: Retrospective case series at a single tertiary care hospital. PATIENTS: A total of 177 children 0-18 years of age at the time of diagnosis of a thyroid nodule and/or malignancy between 1992 and 2012.
RESULTS: There was a significantly higher female-to-male ratio in patients 12-18 years with benign and malignant nodules compared to those under 12. There was no difference across age groups with respect to cytology or histology, size, surgical approach or nodal status. Younger patients had a higher lymph node ratio. Younger patients received a higher cumulative dose of radioactive iodine (97.6 mCi/m2 ) vs older patients (75.9 mCi/m2 ) and had higher rates of pulmonary metastatic disease, although the differences did not achieve significance. Finally, children were less likely than adolescents to achieve a state of undetectable disease and fewer of the younger children remained disease-free.
CONCLUSIONS: Despite comparable apparent initial disease burden and treatment, younger children have poorer outcomes when compared to adolescents, even in the absence of nodal metastases and thus may warrant intensification of primary therapy and/or tumour surveillance.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  adolescence; childhood; papillary thyroid carcinoma; recurrence

Year:  2018        PMID: 29672887     DOI: 10.1111/cen.13720

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  2 in total

1.  Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.

Authors:  Sébastien Perreault; Rose Chami; Rebecca J Deyell; Dina El Demellawy; Benjamin Ellezam; Nada Jabado; Daniel A Morgenstern; Aru Narendran; Poul H B Sorensen; Jonathan D Wasserman; Stephen Yip
Journal:  Curr Oncol       Date:  2021-01-09       Impact factor: 3.677

2.  Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis?

Authors:  Julia Ramalho Amalio da Silva Breder; Paulo Alonso Garcia Alves; Mario Lucio Araújo; Barbara Pires; Priscila Valverde; Daniel Alves Bulzico; Fernanda Andrade Accioly; Rossana Corbo; Mario Vaisman; Fernanda Vaisman
Journal:  Eur Thyroid J       Date:  2022-03-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.